Allergy Therapeutics Market - By Treatment (Anti-allergy drug [Antihistamine, Corticosteroid, Decongestant], Immunotherapy [SCIT, SLIT]), Type (Rhinitis, Asthma, Skin, Food, Eye), Route of Administration, Distribution Channel, Global Forecast, 2023 – 2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAllergy Therapeutics Industry Analysis
Allergy Therapeutics Market size accounted for USD 21.7 billion in 2022 and is expected to reach USD 41.2 billion by 2032, increasing at a CAGR of 6.6% from 2023 to 2032. The rising incidence of allergic disorders is one of the main drivers of the market.
Allergies such as allergic rhinitis, asthma, food allergies, and atopic dermatitis have become more frequent in recent years. According to the CDC's National Centre for Health Statistics, over one-third of U.S. adults and more than one-fourth of U.S. children affected by a seasonal allergy, eczema, or food allergy in 2021. This surge in incidence is linked to causes such as increasing environmental exposures, genetics, growing urbanisation, and lifestyle changes.
Moreover, continuous advances in medical research have resulted in greater understanding of allergic disorders, their underlying processes, and prospective therapy targets. This understanding has aided in the creation of more effective and tailored allergy therapies. In addition, allergic conditions can have a substantial influence on a person's quality of life. The need for effective allergy relief drives the demand for new and improved treatment alternatives that provide greater symptom management and overall well-being.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Allergy Therapeutics Market Size in 2022 | USD 21.7 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 6.6% |
| 2032 Value Projection | USD 41.2 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 215 |
| Tables, Charts & Figures | 374 |
| Segments covered | Treatment type, Type, Route of Administration, Distribution Channel, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic had a significant impact on the allergy therapeutics market. The downtime of global supply chains, including pharmaceutical manufacture and delivery, had hampered the availability of some allergy drugs. This might have resulted in shortages or delays in obtaining specialised therapies. Additionally, many non-urgent healthcare appointments were postponed or cancelled during the early stages of the pandemic, resulting in delayed identification and treatment for allergic diseases. Patients with allergies may have avoided seeking medical attention owing to concerns about being exposed to the virus in hospital settings.
However, the pandemic spurred the usage of telemedicine and virtual consultations. While this allowed healthcare personnel to communicate with patients remotely, it has hindered the capacity to do some tests or examinations necessary for correct allergy diagnosis.
Overall, COVID-19 has a diversified influence on the market. While there were delays and interruptions, there were also potential for enhanced awareness and improved approaches to patient care through telemedicine and other digital alternatives. As the situation evolved, it was critical to conduct continual research and adaptation to ensure that persons with allergies receive proper care and treatment.
Allergy Therapeutics Market Trends
The market is experiencing several notable trends that are shaping its growth and development. Some key trends in the market includes increasing personalized medicine and precision therapies, rising adoption of biologic therapies, such as monoclonal antibodies, are gaining traction in the treatment of severe allergic conditions like asthma and chronic urticaria, innovative methods of allergen immunotherapy, including sublingual tablets, patches, and intratympanic immunotherapy, and increasing integration of digital technologies, including mobile apps, wearables, and telemedicine platforms, is enhancing patient engagement, remote monitoring, and access to allergy specialists.
Moreover, food allergy awareness is increasing, prompting research into novel treatments such as oral immunotherapy and other desensitization approaches. The approval of the first peanut allergy treatment marked a significant milestone in this area.
Allergy Therapeutics Treatment type Segmentation
Based on treatment type, the allergy therapeutics market is segmented as anti-allergy drugs and immunotherapy. The anti-allergy drugs are further segmented into antihistamines, corticosteroids, decongestants, and other drugs. The immunotherapy is further segmented into sub-cutaneous Immunotherapy (SCIT), and sub-lingual Immunotherapy (SLIT). The anti-allergy drugs segment accounted for the largest share of 84% in 2022. The rising prevalence of allergies in children has created a significant demand for paediatric-friendly anti-allergy drugs. Medications designed for children and infants address the unique needs of young patients.
Based on type of anti-allergy drugs, the corticosteroids segment accounted for the highest share in 2022. Corticosteroids come in various forms, including oral tablets, inhalers, nasal sprays, creams, ointments, and injections. This versatility allows for targeted delivery to specific affected areas, making them suitable for treating a wide range of allergic conditions, from asthma to eczema.
Allergy Therapeutics Type Segmentation
Based on type, the allergy therapeutics market is segmented as eye allergy, asthma, skin allergy, food allergies, rhinitis, and other allergy types. The rhinitis segment held dominant market share of around 19.5% in 2022 and is expected to grow at a significant pace of 6.4% during the forecast period. Allergic rhinitis is one of the most common chronic diseases in the globe. It affects a significant percentage of the worldwide population, encompassing a wide range of age groups and demographics. Owing to this high incidence, there is a significant desire for effective therapies that can relieve symptoms and enhance quality of life. Furthermore, seasonal allergens (pollen) or perennial allergens (dust mites, animal dander) can cause allergic rhinitis. The year-round presence of diverse allergy triggers raises the demand for therapeutic options.
Allergy Therapeutics Route of Administration Segmentation
When it comes to treating allergies, different ways are available depending on how the medication is given. You can take it by mouth (oral), inhale it (inhalers), spray it up your nose (intranasal), or use other methods. The oral approach has been the most popular so far, and it's not surprising why. It's easy and convenient. You can pop a pill or swallow a liquid anywhere, anytime. No need to fuss with gadgets or special techniques. And here's the best partit's beginner-friendly. If you're young or old, or if you struggle with other methods like sprays and inhalers, oral medications have got you covered. That's why the demand for oral allergy treatments is set to skyrocket, making it a major player in the market.
Allergy Therapeutics Distribution Channel Segmentation
When buying allergy medicine, people have a few optionsthe hospital pharmacy, the regular pharmacy, or other places. In 2022, the hospital pharmacy was the most popular choice, with over half (54.6%) of all sales. And it's expected to keep growing, with sales predicted to increase by 6.5% each year from 2023 to 2032. Why are hospital pharmacies so popular for allergy medicine? Because when someone has an allergic reaction, they often need help right away. Hospital pharmacies are right there in the hospital, so they can give patients the medicine they need quickly. This is especially important for allergic reactions that can be serious, like those that cause trouble breathing or swallowing. Hospital pharmacies also play a key role in managing allergy treatments and ensuring the well-being of patients overall.
Allergy Therapeutics Regional Analysis
North America allergy therapeutics market accounted for significant revenue in 2022 and is expected to reach USD 17.2 billion in 2032 with a CAGR of 6.7% from 2023-2032. North America has a relatively high prevalence of allergic conditions, including allergic rhinitis, asthma, atopic dermatitis, and food allergies. Environmental factors, genetic predisposition, and lifestyle changes contribute to the widespread occurrence of allergies in the region.
Moreover, awareness about allergic conditions and their impact on health has grown significantly in North America. Greater awareness prompts individuals to seek medical attention, leading to improved diagnosis rates and the demand for effective allergy therapeutics. Additionally, North America boasts advanced healthcare systems with well-established medical facilities, hospitals, clinics, and specialty practices. This infrastructure supports the diagnosis, treatment, and management of allergic conditions, driving the demand for therapeutics, leading to the regional progress.
Allergy Therapeutics Industry Leaders
Some of the major market players operating in the allergy therapeutics market are Allergopharma, Danaher, AbbVie, Inc., Allergy Therapeutics plc, Sanofi SA, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Merck & Co., Inc. These players focus on strategic partnerships, new type launch & commercialization for market expansion.
Allergy Therapeutics Industry News
- In August 2020, Nestlé and Aimmune Therapeutics, Inc. signed an agreement under which Nestlé Health Science (NHSc) acquired Aimmune. Palforzia by Aimmune is the first and only FDA-approved therapy to help reduce the frequency and severity of peanut allergy reactions, including anaphylaxis, in children aged 4 to 17. This acquisition expands NHSc's food allergy portfolio, providing a greater range of options for children with food allergies.
The allergy therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Treatment type, 2018 - 2032 (USD Million)
- Anti-allergy drugs
- Antihistamines
- Corticosteroids
- Decongestants
- Other drugs
- Immunotherapy
- Sub-cutaneous immunotherapy (SCIT)
- Sub-lingual immunotherapy (SLIT)
By Type, 2018 - 2032 (USD Million)
- Eye allergy
- Asthma
- Skin allergy
- Food allergies
- Rhinitis
- Other allergy types
By Route of administration, 2018 - 2032 (USD Million)
- Oral
- Inhalers
- Intranasal
- Other routes of administration
By Distribution Channel, 2018 - 2032 (USD Million)
- Hospital pharmacies
- Retail pharmacies
- Other distribution channels
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy